Trial Profile
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Nirogacestat (Primary) ; SEA-BCMA (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Seagen
- 29 Nov 2023 Status changed from active, no longer recruiting to discontinued due to portfolio prioritization.
- 14 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2022 Updated Results(As of 16 May 2022, n=73) assessing safety and efficacy of Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma presented at the 64th American Society of Hematology Annual Meeting and Exposition